Showing 1451-1460 of 1601 results for "".
- Cynosure's PicoSure Laser Cleared by FDA for Acne Scarshttps://practicaldermatology.com/news/20140801-cynosure_announces_picosure_is_fda-cleared_to_treat_acne_scars/2459153/The FDA cleared the PicoSure picosecond laser to treat acne scars. "We are thrilled to announce that PicoSure, the world's most advanced laser technology for tattoo removal and benign pigmented lesions, has now received FDA-clearance to treat acne scar
- MELA Sciences Reports the Closing of Its Private Placementhttps://practicaldermatology.com/news/20140728-mela_sciences_reports_the_closing_of_its_private_placement/2459156/IRVINGTON, N.Y., July 25, 2014 (GLOBE NEWSWIRE) -- MELA Sciences, Inc. (Nasdaq:MELA), developer of the MelaFind(R) system, an optical diagnostic device approved for use in the United States and the European Union to assist dermatologists in melanoma diagnosis, announced today that it has closed i
- New Patient Education Service from Vivacare Helps Medical Professionals Deliver Health Education at the Point of Carehttps://practicaldermatology.com/news/20140716-new_patient_education_service_from_vivacare_helps_medical_professionals_deliver_health_education_at_the_point_of_care/2459166/Vivacare, a leading provider of patient education services for physicians, today announced a major upgrade to its free, web-based service and the opportunity for physician assistants, nurse practitioners and other medical professionals to enroll. In just minutes, physicians and other medical pr
- MELA Sciences Begins Insurance Reimbursement Process With Application for New CPT Code for the MelaFind Systemhttps://practicaldermatology.com/news/20140715-mela_sciences_begins_insurance_reimbursement_process_with_application_for_new_cpt_code_for_the_melafind_system/2459170/MELA Sciences, Inc. (Nasdaq:MELA), announced today that it has taken the first step in the process of seeking insurance reimbursement for its Multi-Spectral Digital Skin Lesion Analysis (MSDSLA) procedure that is performed by dermatologists utilizing the MelaFind® system as an aid in the detection o
- Advanced Dermatology & Cosmetic Surgery (ADCS Clinics) Acquires The Grekin Skin Institutehttps://practicaldermatology.com/news/20140714-advanced_dermatology__cosmetic_surgery_adcs_clinics_acquires_the_grekin_skin_institute/2459172/ADCS Clinics ("ADCS") announced it has completed the acquisition of The Grekin Skin Institute in Southfield, Michigan, a dermatology practice founded by Dr. Steven Grekin.
- South Beach Symposium Debuts New Host Hotelhttps://practicaldermatology.com/news/20140623-south_beach_symposium_debuts_new_host_hotel/2459198/The 13th annual meeting of the South Beach Symposium moves to the Fontainebleau Hotel in Miami Beach, February 12-16, 2015. Faculty for the event have been announced on the SBS website. There are non-overlapping CME tracks: the Mas
- Valeant Commences Exchange Offer For Allerganhttps://practicaldermatology.com/news/20140618-valeant_commences_exchange_offer_for_allergan/2459200/Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX) (TSX: VRX) today announced that it has commenced an exchange offer for the common stock of Allergan, Inc. ("Allergan") (NYSE: AGN), taking its May 30th proposal directly to Allergan stockholders. Under the terms of the offer, Allerg
- Provectus Biopharmaceuticals will discuss outline of Phase 3 Clinical Trial Of PV-10 To Treat Melanoma on Conference Callhttps://practicaldermatology.com/news/20140612-provectus_biopharmaceuticals_will_discuss_outline_of_phase_3_clinical_trial_of_pv-10_to_treat_melanoma_on_conference_call/2459208/Provectus Biopharmaceuticals, Inc. has announced that it will hold a conference call on Thursday, June 19, 2014, at 4 pm Eastern Daylight Time. Management will discuss the outline of the Company's proposed Phase 3 study of PV-10 in the treatment of melanoma, developments in the use of PV-
- Foamix Establishes U.S. Subsidiary and Strengthens Executive Management With Appointment of Senior U.S. Leadership Teamhttps://practicaldermatology.com/news/20140611-foamix_establishes_us_subsidiary_and_strengthens_executive_management_with_appointment_of_senior_us_leadership_team/2459209/Foamix Pharmaceuticals, a clinical-stage, specialty pharmaceutical company focused on the development, patenting and commercialization of proprietary topical foams to address unmet needs in dermatology, today announced the establishment of its U.S. Subsidiary and appointment of five industry veteran
- New Data Demonstrate Efficacy of ClarityMD OTC Acne Systemhttps://practicaldermatology.com/news/20140611-new_data_demonstrate_efficacy_of_claritymd_otc_acne_system/2459210/Newly published data show the efficacy of Envy Medical's ClarityMD acne system. Results of a clinical study designed by Envy, demonstrate that ClarityMD is effective in quickly and gently clearing both inflammatory and non-inflammatory acn